Tarsus Pharmaceuticals segnala gli utili su base trimestrale. Questi report sugli utili trimestrali offrono agli investitori uno sguardo ai risultati finanziari di un'azienda per un periodo di 3 mesi. I report sugli utili includono quasi sempre i risultati EPS e i ricavi.
Analizza lo storico degli utili di Tarsus Pharmaceuticals utilizzando ordinamenti e filtri avanzati.
Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
TARS | Tarsus Pharmaceuticals | -$0.61 | -$0.34 | -$0.30 | 11.76% | $48.12M | $115.32M | $118.70M | 2.93% | 11/04/2025 | |
TARS | Tarsus Pharmaceuticals | -$0.88 | -$0.35 | -$0.48 | -37.14% | $40.81M | $94.84M | $102.66M | 8.24% | 08/06/2025 | |
TARS | Tarsus Pharmaceuticals | -$1.01 | -$0.63 | -$0.64 | -1.59% | $27.61M | $71.62M | $78.33M | 9.38% | 05/01/2025 | |
TARS | Tarsus Pharmaceuticals | -$1.31 | -$0.82 | -$0.60 | 26.83% | $13.08M | $58.80M | $66.41M | 12.94% | 02/25/2025 | |
TARS | Tarsus Pharmaceuticals | -$1.28 | -$0.94 | -$0.61 | 35.11% | $1.87M | $43.44M | $48.12M | 10.77% | 11/13/2024 | |
TARS | Tarsus Pharmaceuticals | -$1.17 | -$0.93 | -$0.88 | 5.38% | $0.00 | $31.71M | $40.81M | 28.71% | 08/08/2024 | |
TARS | Tarsus Pharmaceuticals | -$0.88 | -$1.20 | -$1.01 | 15.83% | $2.50M | $17.83M | $27.61M | 54.87% | 05/08/2024 | |
TARS | Tarsus Pharmaceuticals | -$0.49 | -$1.36 | -$1.31 | 3.68% | $10.00M | $5.66M | $13.08M | 131.02% | 02/27/2024 | |
TARS | Tarsus Pharmaceuticals | -$0.84 | -$1.36 | -$1.28 | 5.88% | $0.00 | $400.00K | $1.87M | 367.75% | 11/09/2023 | |
TARS | Tarsus Pharmaceuticals | -$0.24 | -$1.08 | -$1.17 | -8.33% | $15.28M | — | $0.00 | — | 08/10/2023 | |
TARS | Tarsus Pharmaceuticals | -$0.98 | -$0.94 | -$0.88 | 6.38% | $539.00K | $3.12M | $2.50M | -19.87% | 05/09/2023 | |
TARS | Tarsus Pharmaceuticals | -$0.72 | -$0.69 | -$0.49 | 28.99% | $338.00K | $10.00M | $10.00M | 0.00% | 03/13/2023 | |
TARS | Tarsus Pharmaceuticals | -$0.76 | -$0.97 | -$0.84 | 13.40% | $1.24M | — | $0.00 | — | 11/09/2022 | |
TARS | Tarsus Pharmaceuticals | $0.29 | -$1.08 | -$0.24 | 77.78% | $22.02M | $13.00M | $15.28M | 17.52% | 08/11/2022 | |
TARS | Tarsus Pharmaceuticals | $0.47 | -$0.92 | -$0.98 | -6.52% | $33.43M | — | $539.00K | — | 05/10/2022 | |
TARS | Tarsus Pharmaceuticals | -$1.85 | -$0.73 | -$0.72 | 1.37% | $0.00 | $338.00K | $338.00K | 0.00% | 03/14/2022 | |
TARS | Tarsus Pharmaceuticals | -$3.71 | -$0.43 | -$0.76 | -76.74% | $0.00 | $5.33M | $1.24M | -76.74% | 11/09/2021 | |
TARS | Tarsus Pharmaceuticals | — | -$0.48 | $0.29 | 160.42% | — | $4.53M | $22.02M | 386.03% | 08/04/2021 | |
TARS | Tarsus Pharmaceuticals | -$0.74 | -$0.64 | $0.47 | 173.44% | — | $33.43M | $33.43M | 0.01% | 05/11/2021 | |
TARS | Tarsus Pharmaceuticals | — | -$0.66 | -$1.85 | -180.30% | — | — | $0.00 | — | 03/31/2021 | |
TARS | Tarsus Pharmaceuticals | — | — | -$3.71 | — | — | — | $0.00 | — | 11/25/2020 |
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q3 | 2025-11-04 | $-0.30 | $-0.34 | 11.8 % |
| Q2 | 2025-08-06 | $-0.48 | $-0.35 | -37.1 % |
| Q1 | 2025-05-01 | $-0.64 | $-0.63 | -1.59 % |
| Q4 | 2025-02-25 | $-0.60 | $-0.82 | 26.8 % |
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q3 | 2025-11-04 | $118.70M | $115.32M | 2.93 % |
| Q2 | 2025-08-06 | $102.66M | $94.84M | 8.24 % |
| Q1 | 2025-05-01 | $78.33M | $71.62M | 9.38 % |
| Q4 | 2025-02-25 | $66.41M | $58.80M | 12.9 % |
Tarsus Pharmaceuticals (TARS) non ha ancora previsto report sulle performance. L'ultimo report sui risultati è stato pubblicato il novembre 4, 2025 per il Q3.
Tarsus Pharmaceuticals (TARS) non ha ancora in programma alcun report sugli utili. L'ultimo report sugli utili è stato pubblicato il novembre 4, 2025 per il Q3 e l'EPS effettivo è stato $-0.30, che superato la stima di $-0.34.
Tarsus Pharmaceuticals (TARS) non ha ancora pianificato alcun report sugli utili. L'ultimo report sugli utili è stato pubblicato il novembre 4, 2025 per il Q3 e i ricavi effettivi sono stati $118.7M, che superato la stima di $115.3M.
Sfoglia stime sugli utili, EPS e ricavi su tutte le azioni.